Interpreting the biological relevance of bioinformatic analyses with T-DNA sequence for protein allergenicity

Autor: Harper, B., McClain, S., Ganko, E.W.

Publikováno v: In Regulatory Toxicology and Pharmacology August 2012 63(3):426-432

Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial:Webinar #4: Molecular testing and patient selection in ovarian cancer How Do We Optimize PROs? ORAL abstract

Autor: Swisher, Elizabeth M, Coleman, Robert L, Bookman, Michael A, Brady, M.F., Fleming, Gini F, Friedlander, Michael, Cunningham, J., Tewari, K.S., Edraki, B, Mantia-Smaldone, G.M., Ratajczak, C. K., Dinh, Minh H, Sullivan, Danielle M, McClain, S, Okubo, S, Dahl Steffensen, Karina, Aghajanian, Carol

Publikováno v: Swisher, E M, Coleman, R L, Bookman, M A, Brady, M F, Fleming, G F, Friedlander, M, Cunningham, J, Tewari, K S, Edraki, B, Mantia-Smaldone, G M, Ratajczak, C K, Dinh, M H, Sullivan, D M, McClain, S, Okubo, S, Dahl Steffensen, K & Aghajanian, C 2020, ' Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial : Webinar #4: Molecular testing and patient selection in ovarian cancer How Do We Optimize PROs? ORAL abstract ', SGO Annual Meeting of Women's Cancer, Toronto, Canada, 28/03/2020-31/03/2020 . < https://www.sgo.org/wp-content/uploads/2020/03/SGO-2020-Annual-Meeting-Oral-Abstracts.pdf >

Objective: The phase 3 VELIA trial demonstrated that veliparib dosed concurrently with carboplatin/paclitaxel and continued as maintenance monotherapy resulted in a statistically significant improvement in progression-free survival compared to carbop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::c69e9e124dd460a01c9e144f74c221fe
https://www.sgo.org/wp-content/uploads/2020/03/SGO-2020-Annual-Meeting-Oral-Abstracts.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial

Autor: Swisher, E.M., Coleman, R.L., Bookman, M.A., Brady, M.F., Fleming, G.F., Friedlander, M., Cunningham, M.J., Tewari, K.S., Edraki, B., Moxley, K., Mantia-Smaldone, G.M., Ratajczak, C., Dinh, M.H., Sullivan, D.M., McClain, S., Okubo, S., Steffensen, K.D., Aghajanian, C.

Publikováno v: In Gynecologic Oncology October 2020 159 Supplement 1:20-21